Neurogene Cash Flow Statement
NASDAQ: NGNEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
26.40-0.10 (-0.38%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Neurogene free cash flow
In fiscal 2025, Neurogene generated -$77.2 million of operating cash flow and spent $1.2 million on capital expenditures. That left free cash flow of -$78.4 million.
Summary generated from market data by MetaCap's automated system. Methodology
Neurogene cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -90.35M | -75.14M | -36.32M | -55.19M | -60.69M | -33.28M | -69.44M | -31.59M | -50.18M | -37.00M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 3.04M | 3.19M | 3.26M | 3.20M | 1.31M | 785.00K | 340.00K | 289.00K | 360.00K | — |
| Stock-Based Compensation | 14.18M | 8.32M | 1.42M | 1.25M | 11.56M | 5.62M | 7.68M | 4.70M | 3.84M | 1.97M |
| Change in Working Capital | 569.00K | -288.00K | -97.00K | -3.61M | 129.00K | -2.48M | 290.00K | — | — | — |
| Operating Cash Flow | -77.17M | -70.60M | -51.42M | -52.82M | -47.56M | -24.57M | -15.39M | -31.58M | -44.72M | -30.23M |
| Capital Expenditures | -1.18M | -808.00K | -321.00K | -2.23M | -3.26M | -2.22M | -879.00K | -49.00K | -494.00K | -713.00K |
| Investing Cash Flow | 14.00M | -125.26M | 25.64M | -2.23M | -3.26M | -2.22M | -688.00K | 55.95M | 64.01M | -48.06M |
| Financing Cash Flow | 30.43M | 184.07M | 92.48M | 66.53M | 732.00K | 77.14M | 82.24M | 570.00K | 423.00K | 71.11M |
| Net Change in Cash | -32.74M | -11.79M | 66.70M | 11.48M | -50.09M | 50.34M | 66.17M | 24.90M | 19.73M | -7.22M |
| Free Cash Flow | -78.36M | -71.41M | -51.74M | -55.05M | -50.82M | -26.79M | -16.27M | -31.63M | -45.21M | -30.94M |
This table shows 10 annual periods of Neurogene's cash flow statement, from FY 2025 back to FY 2016, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow NGNE's reporting calendar. What is a cash flow statement?